4.5 Review

Mir-221/222 are promising targets for innovative anticancer therapy

Journal

EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 20, Issue 9, Pages 1099-1108

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2016.1164693

Keywords

MicroRNA; miRNA; miRNA inhibitors; miR-221; miR-221/222; oligonucleotidebased therapy; cancer; myeloma

Funding

  1. AIRC (the Italian Association for Cancer Research) [9980]

Ask authors/readers for more resources

Introduction: MicroRNAs (miRNAs) are key non-coding RNA post-transcriptional regulators of messenger RNAs (mRNAs), and are deeply dysregulated in human cancer. A rising body of evidence indicates that miRNAs represent valuable therapeutic targets. In this light, the cluster miR-221/222 are of particular relevance, given that they are strongly upregulated in a variety of solid and hematologic malignancies. Area covered: This review summarizes recent findings on the roles played by miR-221/222 in human cancer and their potential clinical value as promising targets for therapeutic studies. Expert opinion: The rising body of advanced preclinical evidence on the biological significance of miR-221/222 in a variety of malignancies indicates that they will play a crucial role in the future of innovative therapeutic strategies, both as validated biomarkers and targets.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available